[go: up one dir, main page]

AR117189A1 - Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) - Google Patents

Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)

Info

Publication number
AR117189A1
AR117189A1 ARP190103182A ARP190103182A AR117189A1 AR 117189 A1 AR117189 A1 AR 117189A1 AR P190103182 A ARP190103182 A AR P190103182A AR P190103182 A ARP190103182 A AR P190103182A AR 117189 A1 AR117189 A1 AR 117189A1
Authority
AR
Argentina
Prior art keywords
carboxamidas
pirazin
pirazolo
dihidro
hbv
Prior art date
Application number
ARP190103182A
Other languages
English (en)
Inventor
Anita Wegert
Jasper Springer
Susanne Bonsmann
Andreas Urban
Alastair Donald
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of AR117189A1 publication Critical patent/AR117189A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicación 1: Compuesto de fórmula (1) en la que R¹, R², R³ y R⁴ se seleccionan, para cada posición, independientemente del grupo que comprende H, CF₂H, CF₃, CF₂CH₃, F, Cl, Br, CH₃, Et, i-Pr, c-Pr, D, CH₂OH, CH(CH₃)OH, CH₂F, CH(F)CH₃, I, C=C, C&
ARP190103182A 2018-11-02 2019-10-31 Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) AR117189A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18000878 2018-11-02

Publications (1)

Publication Number Publication Date
AR117189A1 true AR117189A1 (es) 2021-07-21

Family

ID=64426622

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103182A AR117189A1 (es) 2018-11-02 2019-10-31 Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)

Country Status (15)

Country Link
US (1) US20220081444A1 (es)
EP (1) EP3873910A1 (es)
JP (1) JP2022506337A (es)
KR (1) KR20210099563A (es)
CN (1) CN112996791A (es)
AR (1) AR117189A1 (es)
AU (1) AU2019370734A1 (es)
CA (1) CA3118381A1 (es)
EA (1) EA202191223A1 (es)
IL (1) IL282598A (es)
PH (1) PH12021550970A1 (es)
SG (1) SG11202104116VA (es)
TW (1) TW202031659A (es)
UY (1) UY38434A (es)
WO (1) WO2020089455A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR116947A1 (es) * 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
DK4097099T3 (da) 2020-02-07 2024-07-15 Gasherbrum Bio Inc Heterocyckliske GLP1-agonister
EP4146639A1 (en) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4211139A4 (en) * 2020-09-10 2024-12-18 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑
WO2023009709A1 (en) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Pyrazolo piperazines as jak2 inhibitors
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
JP7782035B2 (ja) 2021-11-09 2025-12-08 エイジャックス セラピューティクス, インコーポレイテッド Jak2阻害剤としての6-ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
CN115232086B (zh) * 2022-07-19 2024-05-03 扬州市普林斯医药科技有限公司 一种4-苄基-2(3h)-噁唑酮的制备方法
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN116396204B (zh) * 2023-03-29 2024-09-24 无锡科华生物科技有限公司 一种4,6,7-三氟-1h-吲哚-2-羧酸的制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19817264A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
AU4289100A (en) 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
DE60033657T2 (de) 1999-04-23 2007-11-08 Extenday IP Ltd., Kumeu Foliebefestigungs- und verankerungsteil
AU3009801A (en) 1999-12-22 2001-07-03 Bayer Aktiengesellschaft Combinations of medicaments for treating viral diseases
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
JPWO2010024258A1 (ja) * 2008-08-29 2012-01-26 塩野義製薬株式会社 Pi3k阻害活性を有する縮環アゾール誘導体
WO2011130163A1 (en) * 2010-04-12 2011-10-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8846684B2 (en) * 2011-03-31 2014-09-30 The Regents Of The University Of Michigan Arbovirus inhibitors and uses thereof
EP2717694A4 (en) 2011-06-10 2014-11-12 Glaxosmithkline Intellectual Property Ltd NEW COMPOUNDS
JP5977347B2 (ja) 2011-07-01 2016-08-24 バルーク エス.ブルームバーグ インスティテュート Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
KR101699822B1 (ko) 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
AU2013207205B2 (en) 2012-01-06 2017-02-02 Janssen Sciences Ireland Uc 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of Hepatitis B
US9096579B2 (en) * 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
AR092269A1 (es) 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CN104797561B (zh) 2012-08-28 2017-03-01 爱尔兰詹森科学公司 稠合二环的氨磺酰基衍生物及其作为药物用于治疗乙型肝炎的用途
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
WO2014152725A1 (en) 2013-03-15 2014-09-25 Biogen Idec Ma Inc. S1p and/or atx modulating agents
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN105209470B (zh) 2013-05-17 2018-02-06 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的6‑桥连的杂芳基二氢嘧啶
SG10201805033XA (en) 2013-07-25 2018-07-30 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015057945A1 (en) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
KR20160127714A (ko) 2013-11-14 2016-11-04 노비라 테라퓨틱스, 인코포레이티드 아제판 유도체 및 b형 간염 감염의 치료 방법
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR101926243B1 (ko) 2014-03-07 2018-12-06 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 및 예방을 위한 6-융합된 헤테로아릴다이하이드로피리미딘
AU2015229174B2 (en) 2014-03-13 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein allosteric modulators
JP2017512789A (ja) 2014-03-28 2017-05-25 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. ジヒドロピリミジン化合物及び医薬におけるその適用
AU2015255656A1 (en) 2014-05-09 2016-11-10 Assembly Biosciences, Inc. Methods and compositions for treating hepatitis B virus infections
JP6506836B2 (ja) 2014-08-14 2019-04-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft B型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
ES2802412T3 (es) 2014-12-02 2021-01-19 Novira Therapeutics Inc Compuestos de sulfonamida inversa a base de sulfuro, alquilo y piridilo para el tratamiento del VHB
WO2016109684A2 (en) 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
KR20170113658A (ko) 2015-03-16 2017-10-12 에프. 호프만-라 로슈 아게 Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3292120B1 (en) 2015-05-04 2019-06-19 H. Hoffnabb-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
JP6598974B2 (ja) 2015-07-21 2019-10-30 エフ.ホフマン−ラ ロシュ アーゲー B型肝炎ウイルス感染症の治療および予防のための新規な三環式4−ピリドン−3−カルボン酸誘導体
WO2017015451A1 (en) 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2017040757A1 (en) 2015-09-02 2017-03-09 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
TWI786639B (zh) 2015-09-15 2022-12-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
ES2794639T3 (es) 2015-11-04 2020-11-18 Qilu Pharmaceutical Co Ltd Forma cristalina, método de preparación y compuesto intermedio de compuesto con anillo dihidropirido
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
MX384836B (es) 2016-03-07 2025-03-14 Enanta Pharm Inc Agentes antivirales contra la hepatitis b
WO2017198744A1 (en) * 2016-05-20 2017-11-23 F. Hoffmann-La Roche Ag Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
CN109476668B (zh) 2016-07-14 2022-03-22 豪夫迈·罗氏有限公司 用于治疗感染性疾病的6,7-二氢-4H-吡唑并[1,5-a]吡嗪和6,7-二氢-4H-三唑并[1,5-a]吡嗪化合物
WO2018011160A1 (en) * 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
EP3484885B1 (en) 2016-07-14 2020-03-04 H. Hoffnabb-La Roche Ag Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CA3036245C (en) 2016-09-13 2021-07-20 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
MX2019010404A (es) 2017-03-02 2019-11-21 Assembly Biosciences Inc Compuestos sulfamida cíclicos y métodos de uso de los mismos.
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
CN111448199A (zh) * 2017-11-02 2020-07-24 艾库里斯有限及两合公司 具有抗乙型肝炎病毒(hbv)活性的新的高活性的氨基-噻唑取代的吲哚-2-甲酰胺
KR20200083552A (ko) * 2017-11-02 2020-07-08 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 활성인 신규 고활성 피라졸로-피페리딘 치환된 인돌-2-카르복스아미드
EP3759110A1 (en) * 2018-02-28 2021-01-06 Novartis AG Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
AR116947A1 (es) * 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38437A (es) * 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
UY38435A (es) * 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)

Also Published As

Publication number Publication date
AU2019370734A1 (en) 2021-05-27
KR20210099563A (ko) 2021-08-12
UY38434A (es) 2020-05-29
EA202191223A1 (ru) 2021-07-29
TW202031659A (zh) 2020-09-01
WO2020089455A1 (en) 2020-05-07
SG11202104116VA (en) 2021-05-28
CN112996791A (zh) 2021-06-18
PH12021550970A1 (en) 2022-03-21
JP2022506337A (ja) 2022-01-17
EP3873910A1 (en) 2021-09-08
IL282598A (en) 2021-06-30
CA3118381A1 (en) 2020-05-07
US20220081444A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
AR117189A1 (es) Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
AR116947A1 (es) Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
AR115131A1 (es) Altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
PE20230376A1 (es) Compuestos moduladores de la diacilglicerol quinasa
CY1125163T1 (el) 2΄-υποκατεστημενα-ν6-υποκατεστημενα πουρινο νουκλεοτιδια για την θεραπεια ιων rna
AR113826A1 (es) Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
BR112017002970A2 (pt) novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
MX374296B (es) Compuestos de pirazina novedosos para el tratamiento de enfermedades infecciosas
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
AR103412A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
JP2016505614A5 (es)
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR112333A1 (es) Pirrolopirimidina y derivados de pirrolopirimidina
AR095561A1 (es) Xantinas sustituidas y su uso en el tratamiento de un trastorno mediado por trpc5
EA201691342A1 (ru) Пиразолоновые соединения и их применение
MX388612B (es) Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos.
AR101696A1 (es) Compuestos de azetidiniloxifenilpirrolidina
EA201891239A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака

Legal Events

Date Code Title Description
FA Abandonment or withdrawal